Edinburgh Cancer Research Centre

Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001

Retrieved on: 
Monday, November 7, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Lymphoma, Ovarian cancer, BCMA, CD20, Edinburgh Cancer Research Centre, Queen Elizabeth Hospital, National Institute for Health and Care Excellence, Brain, Patient, NHL, Wales, Cancer, National Institute, Health care, Cancer Research UK, Innovation, ALL, Lymphoid leukemia, University Hospitals Birmingham NHS Foundation Trust, CAR, Entrepreneurship, CD19, Temozolomide, Healthcare Improvement Scotland, Neoplasm, Prostate cancer, SMC, CTE, Acute lymphoblastic leukemia, Lymphatic system, Antigen, NICE, Drug development, Medicine, Leukemia, Cancer research, MHRA, Therapy, The Queen Elizabeth Hospital, Adelaide, AML, B-cell maturation antigen, Pharmaceutical industry, Vaccine

Aleta Biotherapeutics (Aleta), a privately held immuno-oncology company with novel biologic CAR T engagers that work in synergy with cell therapies to improve outcomes for patients, announces that the U.K.

Key Points: 
  • Aleta Biotherapeutics (Aleta), a privately held immuno-oncology company with novel biologic CAR T engagers that work in synergy with cell therapies to improve outcomes for patients, announces that the U.K.
  • This designation for our biologic CAR T-cell therapy engager ALETA-001 marks an important step in addressing the high unmet need for patients who relapse or progress following CD19-targeted CAR T-cell therapy for blood cancers, such as lymphoma and leukemia, stated Paul Rennert, Co-Founder, Acting Chief Executive Officer and Chief Scientific Officer, Aleta Biotherapeutics.
  • ALETA-001 is an off-the-shelf preclinical biologic program developed to treat and prevent cell therapy relapse of existing CD19-targeted CAR T-cell therapies, termed CAR19 T cells.
  • Aleta Biotherapeutics is an immune-oncology company with a portfolio and platform of novel off-the-shelf biologic CAR T engagers (CTEs) that work in synergy with cell therapies to improve outcomes for patients.

NETRIS Pharma, Orano and Centre Léon Bérard Announce Scientific Collaboration to Develop Novel Antibody Radio-Conjugate Therapies

Retrieved on: 
Tuesday, September 20, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Drug resistance, NCI-designated Cancer Center, Director general, Center, Netrin 1, CLB, Safety, OEIC, Nuclear energy, Development, Epidemiology, Lã Đường, Immunoglobulin G, Neoplasm, Erosion (morphology), Innovation, Antibody, Partnership, EMT, Immunotherapy, Patient, Cancer, Ligand, Organization, Technology, Cell, Solution, Mab, Climate, Secretary of State for Universities, Research, Development and Innovation, Uterine cancer, Immune system, Edinburgh Cancer Research Centre, Radionuclide, Technology transfer, Vaccine, Pharmaceutical industry, Medical imaging, Orano

NETRIS Pharma SAS, a private clinical-stage biopharmaceutical company, announced today that it has entered into a scientific collaboration agreement with Orano and the Centre Lon Brard (CLB) to develop novel Antibody Radio-Conjugates for the treatment of cancer.

Key Points: 
  • NETRIS Pharma SAS, a private clinical-stage biopharmaceutical company, announced today that it has entered into a scientific collaboration agreement with Orano and the Centre Lon Brard (CLB) to develop novel Antibody Radio-Conjugates for the treatment of cancer.
  • Initially, the parties intend to conduct a preclinical proof-of-concept efficacy study with new radio-conjugate targeting Netrin-1, combining Netris monoclonal antibody (mAb) NP137 with undisclosed radioelement from Orano.
  • Both NETRIS Pharma and Orano have entered into this collaboration with Centre Lon Brard based on the potential opportunities brought by novel radioisotope conjugates in oncology.
  • NP137, a humanized monoclonal antibody of isotype IgG1 directed against netrin-1, is the first drug candidate developed by NETRIS Pharma.

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

Retrieved on: 
Monday, September 12, 2022
NCNA, Polyadenylation, Cordycepin, Safety, Adenosine, Edinburgh Cancer Research Centre, ADA, Protide, Gene, Company, European Society for Medical Oncology, Private Securities Litigation Reform Act, Melanoma, Forward-looking statement, U.S. Securities and Exchange Commission, Neoplasm, Patient, AES, Cancer, Oncology, Senior lecturer, Terminology, Goal, Transport, NASDAQ, RNA, Security (finance), GLOBE, Trae tha Truth, SEC, PD-1, Pembrolizumab, ESMO, Pharmaceutical industry, Medical imaging

PARIS, Sept. 12, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced data today from the ongoing NuTide:701 study of NUC-7738 in an oral presentation at the European Society for Medical Oncology (ESMO) Annual Meeting.

Key Points: 
  • PARIS, Sept. 12, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced data today from the ongoing NuTide:701 study of NUC-7738 in an oral presentation at the European Society for Medical Oncology (ESMO) Annual Meeting.
  • Data on NUC-7738 from the Phase 1 part of NuTide:701 showed encouraging signals of anti-tumor activity across a range of tumor types, particularly melanoma.
  • We are excited to further investigate the activity of NUC-7738 in melanoma and other tumor types.
  • We have begun enrolling patients into the Phase 2 part of the study and look forward to sharing these data.

More cancer patients in Africa to benefit from advanced radiation therapy with Elekta Unity MR-Linac

Retrieved on: 
Thursday, November 25, 2021
ACCESS, Man, Unity, Brachytherapy, Management of prostate cancer, Hospital, Neoplasm, Woman, Anatomy, Cancer, Health, Edinburgh Cancer Research Centre, EKTA, Winnipeg International Children's Festival, Calendar, APAC, Medical imaging

STOCKHOLM, Nov. 25, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that its latest African order for Elekta Unity MR-Linac comes less than six months after the company introduced its ACCESS 2025 strategy, which includes giving more than 300 million people access to radiation therapy with the addition of 800 to 1,000 additional Elekta linacs in underserved markets.

Key Points: 
  • As a member of the Elekta MR-Linac Consortium, ICCRC will actively investigate the potential benefits of magnetic resonance-guided radiation therapy (MRgRT) in pediatric oncology.
  • In addition, ICCRC will join hospitals around the world in providing high precision radiation therapy to treat cancer in children.
  • And Elekta Unity uses dynamic real-time adaptation to tailor treatment based on changes in the shape, size and position of the tumor and surrounding anatomy.
  • * Elekta Studio is comprised of multiple medical devices, some of which may not yet be available in all markets.

More cancer patients in Africa to benefit from advanced radiation therapy with Elekta Unity MR-Linac

Retrieved on: 
Thursday, November 25, 2021
ACCESS, Man, Unity, Brachytherapy, Management of prostate cancer, Hospital, Neoplasm, Woman, Anatomy, Cancer, Health, Edinburgh Cancer Research Centre, EKTA, Winnipeg International Children's Festival, Calendar, APAC, Medical imaging

As a member of the Elekta MR-Linac Consortium, ICCRC will actively investigate the potential benefits of magnetic resonance-guided radiation therapy (MRgRT) in pediatric oncology.

Key Points: 
  • As a member of the Elekta MR-Linac Consortium, ICCRC will actively investigate the potential benefits of magnetic resonance-guided radiation therapy (MRgRT) in pediatric oncology.
  • In addition, ICCRC will join hospitals around the world in providing high precision radiation therapy to treat cancer in children.
  • And Elekta Unity uses dynamic real-time adaptation to tailor treatment based on changes in the shape, size and position of the tumor and surrounding anatomy.
  • * Elekta Studio is comprised of multiple medical devices, some of which may not yet be available in all markets.